Drug intelligence / Profile preview

KN064

Development stage: Preclinical
Lead developer: AlphaMab Oncology

Overview

KN064 is an investigational therapeutic candidate being developed by Suzhou Alphamab Co., Ltd. for the treatment of autoimmune diseases. It is currently part of the company's innovation pipeline. While Suzhou Alphamab is known for its focus on multi-specific antibodies and single-domain antibody (sdAb) platforms, the specific molecular target, modality, and mechanism of action for KN064 have not yet been publicly disclosed. The drug is in the early stages of development, with clinical phase information currently unavailable in public disclosures.

Beyond the preview

Go deeper on KN064.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KN064.

Explore the full profile